Available archival pathology specimen or tissue sample from a new biopsy for confirmation of diagnosis by central pathology reading.

At least one prior chemotherapy regimen for dedifferentiated liposarcoma.

No more than 2 prior chemotherapy regimens for dedifferentiated liposarcoma. Note: Any number of non-chemotherapy regimens is permitted.

Measurable disease on computed tomography (CT) or magnetic resonance imaging (MRI) as defined by RECIST (version 1.1) with at least one measurable lesion.

Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1.

Life expectancy ≥6 months.

Exclusion Criteria:

Prior treatment with any heat shock protein 90 (Hsp90) inhibitor.

Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable disease

Patients with prior hepatic resections or hepatic-directed therapy

Use of a medication or food that is a clinically relevant CYP3A inhibitor or inducer within 2 weeks prior to dosing.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00969917